studies of AS in intermediate-risk disease have been limited by small sample sizes, short follow-up, and lack of definitive clinical outcomes, including metastasis and prostate cancer–specific mortality (PCSM). 5 – 12 Nevertheless, the use of AS in
Search Results
Metastasis and Mortality in Men With Low- and Intermediate-Risk Prostate Cancer on Active Surveillance
P. Travis Courtney, Rishi Deka, Nikhil V. Kotha, Daniel R. Cherry, Mia A. Salans, Tyler J. Nelson, Abhishek Kumar, Elaine Luterstein, Anthony T. Yip, Vinit Nalawade, J. Kellogg Parsons, A. Karim Kader, Tyler F. Stewart, and Brent S. Rose
CLO23-048: Disparities in Outcomes of Chemotherapy-Related Febrile Neutropenia Patients: A Nationwide Study of Hospitalizations
Akhil Jain, Sohiel Deshpande, Krishna Desai, Sabah Iqbal, Aisha Sultan, Monika Garg, Bohdan Baralo, and Rajesh Thirumaran
analyze the regional disparities in the outcomes of hospitalized FN patients. Methods: Using NIS 2016-19 datasets, we identified chemotherapy related FN hospitalizations (ICD-10-CM codes) and analyzed (weighted) for differences in demographics, admitting
Benefit of Postoperative Radiotherapy for Patients With Nonmetastatic Adrenocortical Carcinoma: A Population-Based Analysis
Kan Wu, Xu Liu, Zhihong Liu, Yiping Lu, Xianding Wang, and Xiang Li
recurrence, leading to a poor prognosis. 4 Therefore, there is an urgent need for adjuvant treatment intensification to prevent disease recurrence and improve survival outcomes. Currently, mitotane monotherapy, cytotoxic drugs, and radiotherapy (RT) are
QIM22-191: Expansion of Tobacco Cessation Treatment Within the Stanford Cancer Institute: 6-Month and 24-Month Outcomes
Amy Chieng, Maura Chandler, Cindy Tran, Brittany Pike, Alexandra Liu, LittleDove Faith Rey, Lauren Haruno, Annemarie Jagielo, Amy Pirkl, and Judith J Prochaska
cessation treatment into cancer care. The funding, technical, and peer support from the C3I collaboration was instrumental in extending Stanford’s tobacco treatment service into 20+ clinics across 3 cancer centers. Aim : To report on patient outcomes at 6
CLO20-067: Clinical Characteristics, Management and Outcome of Incidental Pulmonary Embolism in Cancer Patients: A Case-Control Study
Sai-Ching Yeung, Aiham Qdaisat, Mona Kamal, Aisha Al-Breiki, Biman Goswami, Carol C. Wu, Shouhao Zhou, Terry Rice, and Kumar Alagapan
Incidental pulmonary embolisms (IPE) are commonly discovered in cancer patients during their cancer staging and surveillance imaging studies. Examining the clinical characteristics and outcomes of these incidents in cancer patients may guide the
Association of Chronic Immune-Mediated Diarrhea and Colitis With Favorable Cancer Response
Fangwen Zou, Hamzah Abu-Sbeih, Weijie Ma, Yuanzun Peng, Wei Qiao, Jianbo Wang, Amishi Y. Shah, Isabella C. Glitza Oliva, Sarina A. Piha-Paul, John A. Thompson, Hao Chi Zhang, Anusha S. Thomas, and Yinghong Wang
Background Immune checkpoint inhibitor (ICI) therapy significantly improves cancer outcomes by targeting CLTA-4 or PD-1/L1 and boosting T-cell–mediated immune responses and antitumor effects. 1 , 2 ICIs are widely used as first-line therapy
QIM20-125: OBESE: Oncologist Based Emphasis on Survivor Education-Physician Driven Weight Loss Counseling and Outcomes in TNBC
Marwah W. Farooqui, Caitlin Carter, Nicholas Gustafson, Saherish Abbasi, Sravani Sagireddy, Kathryn Hockensmith, Amy Stein, Masood Ghouse, and Krishan Srinivasan
Obesity has an association with triple negative breast cancer (TNBC). Healthy diet, weight loss, and exercise have lead to favorable outcomes (overall survival [OS], progression free survival [PFS],quality of life [QOL])in TNBC. We aim to highlight
HSR21-041: Impact of Cardiac Comorbidities on Outcomes After Treatment for Locally Advanced Esophageal Cancer: An Institutional Experience
Luis Aguirre, Jacques Fontaine, Jessica Frakes, Sarah Hoffe, Jose Pimiento, and Rutika Mehta
of cardiac comorbidities impacted the outcomes of patients who underwent trimodality therapy for esophageal cancer. Methods: After IRB approval, we collected data on patients treated at our center for locally advanced disease and received
EHR-Integrated Patient-Reported Outcomes in Ambulatory Oncology: A Critical Opportunity for Timely and Targeted Palliative Care
Patricia I. Moreno, Frank J. Penedo, Felicia M. Knaul, Carina Oltmann, Michael T. Huber, and Mariana Khawand-Azoulai
The aim of systematic symptom screening and monitoring using patient-reported outcomes (PROs) is to collect actionable data and provide responsive care that is centered around patients’ needs. Recent evidence demonstrates that routine assessment
Letter to the Editor: Integrating Skeletal Muscle Mass and Radiodensity Improves Outcome Prediction and Correlation in Oncologic Studies
Grant R. Williams, Marc S. Weinberg, and Shlomit S. Shachar
dichotomizing participants as high or low radiodensity, why not integrate these 2 variables into 1 continuous variable? Because both muscle mass and radiodensity are defined independently and both are prognostic of many adverse cancer outcomes, we have proposed
